Published in:

01-01-2005

Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor

Authors: John L. Marshall, Hedy Kindler, John Deeken, Pankaj Bhargava, Nicholas J. Vogelzang, Naiyer Rizvi, Taina Luhtala, Stacy Boylan, Margaret Dordal, Philmore Robertson, Michael J. Hawkins, Mark J. Ratain

Published in: Investigational New Drugs | Issue 1/2005